| DC Field | Value | Language |
|---|
| dc.contributor.author | Șcerbatiuc, Cristina | - |
| dc.contributor.author | Bendelic, Eugeniu | - |
| dc.contributor.author | Paduca, Ala | - |
| dc.date.accessioned | 2023-04-12T07:41:27Z | - |
| dc.date.available | 2023-04-12T07:41:27Z | - |
| dc.date.issued | 2021 | - |
| dc.identifier.citation | ȘCERBATIUC, Cristina, BENDELIC, Eugeniu, PADUCA, Ala. Atropine use in myopia control. In: 19th Black Sea Ophthalmological Society Congress, September 24-26, 2021, Chisinau, Republic of Moldova: abstract book, p. 75. | en_US |
| dc.identifier.uri | https://aom.md/wp-content/uploads/2021/10/ABSTRACT-BOOK_web.pdf | - |
| dc.identifier.uri | http://repository.usmf.md/handle/20.500.12710/24115 | - |
| dc.description.abstract | Atropine is currently the most effective therapy for myopia control. Recent clinical trials
demonstrated low-dose atropine eye drops such as 0.01% resulted in retardation of myopia
progression, with less side effects compared to higher concentration preparation. For children aged
6-10 years with myopia of at least 1D and myopia progression of at least 0.50D per year, the WHO
recommends atropine as a potential first line treatment for myopia. Proposed strategies include a
combination of low-dose atropine with increase outdoor time.
We made pilot study and 1-year results suggest that atropine 0.01% eyedrops can slow myopia
progression and axial elongation of the eye. | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Black Sea Ophthalmological Society, Ophthalmological Association from Moldova, Nicolae Testemitanu State University of Medicine and Pharmacy of the Republic of Moldova | en_US |
| dc.relation.ispartof | 19th Black Sea Ophthalmological Society Congress, September 24-26, 2021 Chisinau, Republic of Moldova | en_US |
| dc.title | Atropine use in myopia control | en_US |
| dc.type | Other | en_US |
| Appears in Collections: | 19th Black Sea Ophthalmological Society Congress, September 24-26, 2021 Chisinau, Republic of Moldova
|
